<DOC>
	<DOCNO>NCT00002385</DOCNO>
	<brief_summary>To identify dos fozivudine tidoxil well tolerate produce measurable antiviral activity . To identify adverse event profile defines maximum tolerate dose . To characterize single- multiple-dose pharmacokinetics fozivudine metabolite . To correlate adverse event profile antiviral activity fozivudine pharmacokinetic parameter .</brief_summary>
	<brief_title>The Safety Effectiveness Fozivudine Tidoxil HIV-1 Infected Patients</brief_title>
	<detailed_description>In double-blind , dose-escalating study , patient receive fozivudine tidoxil one 5 dosage level 4 week randomize respect once- twice-daily administration ( cohorts 2 vs. 3 4 vs. 5 ) . Within cohort , 10 patient randomize study drug 2 placebo . At least 9 12 patient enrol Cohort 1 must complete entire 4-week course Cohorts 2 3 enrol . At least 18 24 patient must complete 2 week 4-week course Cohorts 4 5 enrol .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Primary secondary prophylaxis opportunistic infection stable initiate least 3 month prior study drug administration . Patients must : HIVpositive status . One HIV RNA count &gt; 10,000 copies/ml within 30 day prior entry , second count least 3fold first value . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Active medical problem include chronic diarrhea active opportunistic infection cryptococcosis , Pneumocystis carinii , histoplasmosis , etc.. Malignancy systemic therapy radiation therapy expect required study . Any disease condition would place patient undue risk confound result study . Concurrent Medication : Excluded : Systemic therapy malignancy . Prior Medication : Excluded : Zidovudine nucleoside reverse transcriptase inhibitor . Immunomodulators within one month prior study drug administration . Investigational drug within 30 day prior study drug administration . Systemic cytotoxic chemotherapy within 3 month prior study drug administration . Prior Treatment : Excluded : Extendedfield radiation therapy within 3 month prior study drug administration . Blood transfusion within 2 week prior study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1999</verification_date>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Cohort Studies</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>